ArticleObesity surgery2025
Ten Year Follow-Up After Explantation of the Duodenal-jejunal Bypass Liner.
Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe duodenal-jejunal bypass liner (DJBL) is a treatment for weight loss and diabetes management. While its short-term benefits are known, long-term outcomes of this endoscopic procedure remain largely unknown. This study investigates the long-term effects of DJBL placement on weight, diabetes, and quality of life (QoL) over a period of approximately 10 years post-explantation.
methodsA cross-sectional follow-up study was conducted in 103 former DJBL patients who had DJBL implantation (also known as the Endobarrier) between 2011 and 2014. Participants completed a questionnaire assessing their health, weight, lifestyle, diabetes control, and QoL. Data were compared to original cohort results.
resultsAfter approximately 10 years, weight, BMI, and HbA1c levels remained significantly improved compared to the time of DJBL explantation (p < 0.05). Of the respondents, 33 (32%) had undergone metabolic bariatric surgery (MBS) post-explantation, with significant reductions in weight and BMI observed in this group. MBS was associated with better diabetes control and higher QoL scores compared to non-MBS patients. No significant differences in diabetes-related complications were seen between the MBS and non-MBS groups. GLP-1 agonists use was associated with a higher BMI but did not significantly affect weight, diabetes control, or QoL outcomes.
conclusionsAlthough DJBL treatment has some sustained benefits regarding weight and diabetes management, these effects are limited without further weight-reducing interventions. MBS following DJBL explantation leads to more substantial weight loss and improved diabetes outcome, highlighting its complementary role after DJBL treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.